The primary areas of savings included staffing reductions, decreased travel, and lower outside service expense.

May 7, 2025 / receipt, needs a key / Joe Buskey, CFO | earnings call 2025-05-07 | transcript 49647f20-5cfe-4715-9476-76978bcd1a53 | chars 12691-12802 | segment 12

Yeah, it's a lot of costs. It really cuts across the entire P&L. It's everything from supply chain logistics costs, packaging, to travel and entertainment costs. It really just cuts across the whole P&L. It's a lot of our service costs and IT and quality, et cetera, and even some R&D expenditures. So it really is a broad-based approach that we've taken to the indirect side.

Feb 12, 2025 / receipt, needs a key / Brian, CFO | earnings call 2025-02-12 | transcript 390226d5-b9b9-4a97-a666-821db64469c1 | chars 25398-25774 | segment 26

Yeah, so as Joe mentioned earlier, we're really looking at a number of cost and business process improvement initiatives across the P&L. whether it's in direct costs for our products, which includes everything from instrument components to plastics, biologics, chemicals, to a lot of the indirect costs, travel and entertainment, distribution, freight, logistics, seeing what more we can do to be more efficient in R&D, etc.

Nov 7, 2024 / receipt, needs a key / Brian, other | earnings call 2024-11-07 | transcript 0b37caed-c13c-4035-9b08-02a5e0df7bb0 | chars 31818-32242 | segment 32

As I said before, it's the increase in respiratory revenue, which carries high margins, and then expense management. You know, I said on the prepared remarks that we expect the SG&A in Q4 to come down to closer to where it was at Q2 levels. So we're expecting, you know, a drop down in expense.

Nov 1, 2023 / receipt, needs a key / Joe, CFO | earnings call 2023-11-01 | transcript 9890a466-d20c-4204-bc87-ee247a03e7d8 | chars 38942-39236 | segment 39

We also realized increased travel and meeting costs.

Aug 5, 2021 / receipt, needs a key / Kristen Kaltreiter, CFO | earnings call 2021-08-05 | transcript fad70c9f-08da-4c9e-9a51-4bab2273348b | chars 17725-17777 | segment 18

Travel. We're providing tests for a couple countries right now where they are testing inbound passengers upon their arrival. I suspect other countries will do something similar moving forward.

May 6, 2021 / receipt, needs a key / Doug, CEO | earnings call 2021-05-06 | transcript cdbad145-f7cc-4831-8c10-f59a605ba2eb | chars 22775-22967 | segment 23

For the first time, we have modest inventory but have significant interest from what we call new markets, which include many categories like travel, entertainment, sports, and dining.

Feb 18, 2021 / receipt, needs a key / Doug Bryant, CEO | earnings call 2021-02-18 | transcript 284aea66-fa14-4d12-a274-dd4b32139f59 | chars 8398-8581 | segment 8

Considering first-quarter 2026 performance and current market dynamics in China, the Company has updated its previously provided financial guidance as of 5/5/26.

ir_statement / Sep 16, 2026 / receipt

Toxicology Expansion

ir_statement / Sep 16, 2026 / receipt

VITROS & ECL Menu Expansion

ir_statement / Sep 16, 2026 / receipt

Cost structure improvement

ir_statement / Sep 16, 2026 / receipt

Optimize product economics through design and process excellence

ir_statement / Sep 16, 2026 / receipt

Continued cost-savings initiatives

ir_statement / Sep 16, 2026 / receipt

Decreased CapEx

ir_statement / Sep 16, 2026 / receipt

Decreased inventory

ir_statement / Sep 16, 2026 / receipt

Companywide focus on increasing free cash flow, including management incentives tied to achievement

ir_statement / Sep 16, 2026 / receipt

Cost-savings initiatives for direct procurement and facility consolidation underway

ir_statement / Sep 16, 2026 / receipt

50% Recurring free cash flow conversion target in 2H’27

ir_statement / Sep 16, 2026 / receipt

Adjusted EBITDA margin expansion +240 bps FY25

ir_statement / Sep 16, 2026 / receipt